Tagrisso is a third-generation oral tyrosine kinase inhibitor (TKI) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy. 

If you have a Hayes login, click here to view the full report on the Knowledge Center.